Novo Nordisk (NVO) to be ‘Market Leader’ Despite ‘Horrifying’ Declines
We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take ...
Enrolment concludes in Zealand’s Phase IIb obesity therapy trial
Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing the long-acting amylin analogue, petrelintide, in individuals with obesity or overweight and ...